For more than 20 years, NIAID has funded the Sexual Awareness for Everyone (SAFE) study at The University of Texas Health Science Center San Antonio to reduce risky behaviors that often lead to sexually transmitted diseases.
Chlamydia, a curable sexually transmitted disease (STD), is the most frequently reported bacterial STD in the United States. It is estimated that there are approximately 2.8 million new cases of chlamydia in the United States each year. In 2011, 1,421,791 cases of chlamydial infections were reported to the Centers for Disease Control and Prevention from 50 states and the District of Columbia. Chlamydia cases frequently go undiagnosed and can cause serious problems in men and women, such as penile discharge and infertility respectively, as well as infections in newborn babies of infected mothers.
Scientists are looking for better ways to diagnose, treat, and prevent chlamydia. For example, NIAID researchers at the Instiute's Rocky Mountain Laboratories in Hamilton, Montana, are developing a vaccine to prevent Chlamydia trachomatis infection. The vaccine being tested is a single-component vaccine that is designed to protect against all 15 chlamydia varieties. Studies have already shown that the vaccine can prevent laboratory cells from becoming infected.
More NIAID Research on Chlamydia
Experimental Vaccine Protects Monkeys from Blinding Trachoma—Oct. 11, 2011
News from NIAID-Supported Institutions
Last Updated December 13, 2012
Last Reviewed November 10, 2010